Launched on 6 October 2026Last updated on

Acute pulmonary oedema: cardiogenic vs non-cardiogenic and emergency treatment

Separates cardiogenic from non-cardiogenic acute pulmonary oedema using the natriuretic peptide (BNP < 100 or NT-proBNP < 300 pg/mL rules out acute heart failure; BNP > 400 or the age-adjusted NT-proBNP of 450, 900 or 1800 pg/mL rules it in), bedside echo and lung ultrasound (LV function, valves, IVC, B-line pattern, effusions), ECG and troponin, the chest X-ray and the history (heart disease, fluids, transfusion within 6 h, sepsis, aspiration, trauma, neurological injury, altitude, airway obstruction, re-expansion, drugs), with PAWP when measured. Cardiogenic oedema is typed as hypertensive (SCAPE, flash oedema), ACS, acute valve or mechanical, arrhythmia, volume overload, TACO or cardiogenic shock, with the ESC CHAMPIT precipitants, the warm/cold and wet/dry profile and the BP class. The emergency lines follow ESC 2021 (2023 update) and ACC/AHA/HFSA 2022: sit up, oxygen only for SpO₂ < 90%, CPAP or BiPAP for respiratory distress, intubation criteria, the first IV loop diuretic dose (20–40 mg furosemide if naïve, 1–2 × the daily oral dose otherwise, with bumetanide and torasemide equivalents), the urine sodium and output check with dose doubling, acetazolamide or a thiazide for resistance, IV nitroglycerin or nitroprusside when SBP > 110 mmHg (not after a PDE5 inhibitor, caution in severe AS), why morphine is not routine, inotropes only for hypoperfusion, and treatment of the cause. Non-cardiogenic oedema and ARDS: P/F severity, lung-protective tidal volume from predicted body weight, prone positioning, conservative fluids and the special causes (TRALI, high altitude, negative-pressure and re-expansion oedema).

Upload a report, lab sheet or echo picture to fill this calculator automatically.
Vital signs
SBP decides the vasodilator; SpO₂ and RR decide oxygen and NIV
Natriuretic peptide
Rule-out < 300 pg/mL; rule-in > 900 pg/mL (age-adjusted: 450 < 50 y, 900 at 50–75, 1800 > 75)
Cardiogenic clues
History, examination, POCUS (echo, IVC, lung), chest X-ray
Non-cardiogenic clues
ARDS and other permeability or special causes
Precipitant (CHAMPIT and more)
ACS, Hypertension, Arrhythmia, Mechanical cause, Pulmonary embolism, Infection, Tamponade
Oxygenation and ventilation
P/F ratio for ARDS severity; height and sex for the tidal volume
Acute pulmonary oedema
Not enough information yet
Add the natriuretic peptide, a bedside echo and lung ultrasound, ECG, troponin and the chest X-ray, and tick the history.
Decision guide
Sit up, oxygen if SpO₂ < 90%, and do the bedside echo, lung ultrasound, ECG, troponin and natriuretic peptide.
Clues for a cardiac cause 0 · for a non-cardiac cause 0 (PAWP and the natriuretic peptide count double).
Cardiogenic vs non-cardiogenic at the bedside
No single test decides; combine them
TestCardiogenicNon-cardiogenic (ARDS)
HistoryHeart disease, orthopnoea, PND, fluid or salt excess, missed dialysisSepsis, pneumonia, aspiration, trauma, pancreatitis, transfusion, drugs
ExaminationCool peripheries, S3, raised JVP, peripheral oedema, murmurWarm peripheries (sepsis), no S3, normal JVP
BNP / NT-proBNPHigh (BNP > 400, NT-proBNP > 900)Low (BNP < 100, NT-proBNP < 300)
ECG / troponinIschaemia, LVH, arrhythmia; rising troponinOften normal (troponin can rise in sepsis)
POCUS echoPoor LV, dilated LA, severe valve lesion, plethoric IVCNormal LV and valves, small IVC
Lung ultrasoundDiffuse homogeneous bilateral B-lines, smooth pleura, bilateral effusionsPatchy B-lines with spared areas, irregular pleura, sub-pleural consolidation
Chest X-rayCardiomegaly, upper-lobe diversion, Kerley B, peri-hilar bat-wing, effusionsPeripheral patchy infiltrates, air bronchograms, normal heart size
PAWP (if measured)> 18 mmHg≤ 18 mmHg
Response to diureticRapid improvementLittle change
Recommendations
ESC 2021 heart failure guideline with the 2023 focused update, beside ACC/AHA/HFSA 2022
Acute heart failure with pulmonary oedema
ESC
  • Oxygen for SpO₂ < 90% or PaO₂ < 60 mmHg
    IESC 2021
  • NIPPV for respiratory distress (RR > 25, SpO₂ < 90%), started as soon as possible
    IIaESC 2021
  • IV loop diuretics for all patients with fluid overload
    IESC 2021
  • Loop + thiazide-type diuretic in resistant oedema
    IIbESC 2021
  • IV vasodilators when SBP > 110 mmHg
    IIbESC 2021
  • Inotropes in SBP < 90 with hypoperfusion; norepinephrine in cardiogenic shock
    IIbESC 2021
  • Routine opiates and routine inotropes not recommended
    IIIESC 2021
  • Intensive post-discharge GDMT up-titration and early follow-up
    IESC 2023
ACC/AHA
  • IV loop diuretics promptly for congestion to improve symptoms and reduce morbidity
    1ACC/AHA 2022
  • Inadequate diuresis: higher IV loop dose or a second diuretic (thiazide, acetazolamide, MRA)
    2aACC/AHA 2022
  • IV nitroglycerin or nitroprusside as an adjunct to diuretics without hypotension
    2bACC/AHA 2022
  • Cardiogenic shock: IV inotropes or MCS to maintain perfusion; multidisciplinary shock team
    1ACC/AHA 2022
  • Continue GDMT unless haemodynamically unstable; VTE prophylaxis
    1ACC/AHA 2022
Print / Save PDF: opens the print dialog with a table of the inputs and result; choose Save as PDF to keep a file. Made on this device only; nothing is uploaded.
References
  1. McDonagh TA, Metra M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-3726.
  2. McDonagh TA, Metra M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023;44:3627-3639.
  3. Heidenreich PA, Bozkurt B, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure. Circulation 2022;145:e895-e1032.
  4. Mullens W, Damman K, et al. The use of diuretics in heart failure with congestion: a position statement from the Heart Failure Association of the ESC. Eur J Heart Fail 2019;21:137-155.
  5. Felker GM, Lee KL, et al. Diuretic strategies in patients with acute decompensated heart failure (DOSE). N Engl J Med 2011;364:797-805.
  6. Mullens W, Dauw J, et al. Acetazolamide in acute decompensated heart failure with volume overload (ADVOR). N Engl J Med 2022;387:1185-1195.
  7. Trullàs JC, Morales-Rull JL, et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J 2023;44:411-421.
  8. Gray A, Goodacre S, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema (3CPO). N Engl J Med 2008;359:142-151.
  9. Januzzi JL, van Kimmenade R, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients (ICON). Eur Heart J 2006;27:330-337.
  10. Mebazaa A, Yilmaz MB, et al. Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the HFA, EuSEM and SAEM. Eur J Heart Fail 2015;17:544-558.
  11. Matthay MA, Arabi Y, et al. A new global definition of acute respiratory distress syndrome. Am J Respir Crit Care Med 2024;209:37-47.
  12. Grasselli G, Calfee CS, et al. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive Care Med 2023;49:727-759.
  13. Guérin C, Reignier J, et al. Prone positioning in severe acute respiratory distress syndrome (PROSEVA). N Engl J Med 2013;368:2159-2168.
  14. Mebazaa A, Davison B, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF). Lancet 2022;400:1938-1952.